// App-Quantinova.ai

713 : Minimal Residual Disease Levels At Time Of CR1 and Transplant Predict Outcome In Philadelphia Chromosome-Negative Adult ALL

Researchers

Presenter

  • Mingming Zhang

Principal Investigators

  • Yi Luo

  • Xiaoyu Lai

  • Yamin Tan

  • Weiyan Zheng

  • Yuanyuan Zhu

  • Jimin Shi

  • He Huang

Medical Centers

  • Cancer Biotherapy Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

  • Bone Marrow Transplantation Center, , the First Affiliated Hospital, Zhejiang University School of Medicine,

  • Cancer Biotherapy Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Vincristine

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved